Metropolis Healthcare Ltd.
530.60
INR
-3.00
(-0.56%)
ISIN
INE112L01020
Return %
Stock
S&P 500
1Y
9.97
14.20
3Y
40.85
81.12
5Y
-24.53
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Surendran Chemmenkotil
- Full Time Employees
- 4,844
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- East Wing, Plot-254 B, Nirlon House Mumbai MA India 400030
- IPO Date
- Apr 15, 2019
- Website
- metropolisindia.com
- Similar Companies
- Business
- Metropolis Healthcare Limited Metropolis Healthcare Limited (METROPOLIS.NS) operates as a leading provider of diagnostic pathology and laboratory services in India and select international markets. Founded in 1980 and headquartered in Mumbai, Maharashtra, the company maintains a central reference laboratory in Mumbai alongside a network exceeding 170 advanced clinical labs, over 2,000 patient touchpoints, and collection centers spanning India, Africa (including Ghana, Kenya, Zambia, Uganda), South Asia (Sri Lanka, Mauritius), and the Middle East (UAE). It delivers a comprehensive portfolio of over 4,000 clinical laboratory tests and profiles across routine pathology (biochemistry, immunology, hematology, urine analysis, microbiology), advanced diagnostics (molecular, genetic, cytogenetic testing), semi-specialty and super-specialty domains (oncology, neurology, gynecology, nephrology), imaging services, wellness solutions (pre-employment check-ups, employee health plans, executive health packages, TruHealth preventive screenings), hospital laboratory management and outsourcing for multi-specialty facilities, and clinical trial support services including specimen logistics, analysis, data management, and long-term storage for contract research organizations and pharmaceutical manufacturers; all supported by NABL- and CAP-accredited labs, home sample collection, pediatric expertise, and digital reporting platforms. Geographically, Metropolis Healthcare Limited focuses on urban and Tier II/III markets in India while expanding internationally through established subsidiaries and partnerships, serving individual patients, hospitals, corporates, and physicians with science-led, high-accuracy diagnostics. In recent developments within the last 1-2 years, the company has aggressively pursued its "String of Pearls" acquisition strategy with four key deals to bolster geographic footprint and specialty capabilities: the April 2025 acquisition of Dehradun-based Dr. Ahuja’s Pathology and Imaging Centre for ₹35 crore to deepen North India presence; the March 2025 purchase of Scientific Pathology in Agra, Uttar Pradesh, for ₹55-83 crore, elevating North revenue share from 8% to 13-18% by FY26; the August 2025 buyout of Core Diagnostics in Delhi-NCR for ₹247 crore to enhance oncology expertise; and the September 2025 integration of Kolhapur’s Ambika Pathology Laboratory to strengthen Western Maharashtra operations; these moves, funded primarily through internal accruals, complement ongoing investments in genomics, AI-driven wellness, high-value testing, and a new oncology center of excellence while reporting 23% Q1FY26 revenue growth to ₹386 crore.